Integrated CAM and Pharmacology Notes (Nursing)

CAM and Integrative Health Overview

• Integrative approach to care: combine complementary and alternative therapies with conventional medicine to treat the patient as a whole (body, mind, and soul).
• Examples of integrative/alternative therapies discussed: Tai Chi, massage therapy, mindfulness-based approaches, and other mind–body practices.
• Eastern medicine perspective: emphasis on protecting the body, mind, and soul; belief in a broader system beyond the physical body; some patients may hold a belief in a soul or spirit as part of healing.
• Western and biological-based therapies mentioned: herbal remedies, vitamins, probiotics; microbiome relevance to health (gut microbiome as a factor in many conditions); historical note about evolving research in microbiome over the last ~15 years.
• Healing modalities mentioned besides conventional care: Reiki (described as energy healing), cupping, crystals and other energy-based beliefs; acupuncture, chiropractor, homeopathy, naturopathy, guided imagery, and meditation were noted as CAM therapies requiring varying levels of training.
• Evidence base and research caveats: some CAM therapies have limited high-quality evidence; students encouraged to seek credible sources (research can be sparse or outdated for some CAM modalities); caution about unregulated products and variable potency.
• Personal landscape of CAM: many patients self-treat with herbs, vitamins, or natural products; patient education is essential to safety, especially around potential drug–herb interactions.
• Connection to lifestyle and environment: nonpharmacologic approaches (yoga, herbal gardens, mind-body practices) can influence healing, but must be integrated with medical care and informed consent.

CAM Categories and Examples Mentioned

• Mind–body therapies: meditation, guided imagery, breath work, relaxation techniques, visualization.
• Energy therapies: Reiki (energy healing), crystals (tourmaline mentioned for negative energy beliefs).
• Body-based and manipulative therapies: massage therapy, chiropractic care, cupping, acupuncture (not all details given but listed as CAM modalities).
• Biological-based therapies: herbs (garlic, ginseng, ginkgo, St. John’s wort, valerian), vitamins, probiotics; dietary approaches (crucial to assess for interactions).
• Herbal and dietary supplement interactions emphasized:
  • Garlic: antiplatelet effects; potential interaction with warfarin; monitor coagulation tests (COAGs: INR, PT, aPTT).
  • Ginkgo and ginseng: potential interactions with bleeding or cardiovascular effects; important to review with providers before procedures.
  • St. John’s wort: known to reduce the effectiveness of oral contraceptives and interact with multiple medications.
  • Valerian: used for sleep; reported to improve sleep in some patients when used with other treatments.
  • Licorice root: can contribute to hypertension and tachycardia; monitor with cardiac meds.
• Recreational and other considerations (as discussed informally): discussions around mushrooms, truffles, and other substances; emphasis on safety, legality, and evidence base.
• Culinary and garden-based CAM references: speaker’s personal garden (garlic, basil, lemon, guava, fruit trees) used to illustrate access to plant-based therapies but not as medical advice.

Readiness, Beliefs, and Trust in Healthcare

• Readiness and belief systems shape acceptance of CAM and conventional care; ask patients what healing means to them and how they view preventive care.
• Varied perspectives on healing: some view healing as prevention (healthy lifestyle), others as recovery after illness, and some rely on beliefs in spiritual or energy-based factors.
• Trust in the healthcare system is variable; anecdotes illustrate patients delaying or refusing conventional treatments (e.g., chemotherapy) due to distrust or alternative beliefs.
• Ethical and practical implications: clinicians should respect patient beliefs while clearly communicating risks and benefits of conventional treatments; ensure informed consent and shared decision-making.
• Importance of discussing CAM use openly with providers to avoid unsafe combinations and ensure coordination of care.

Medication Reconciliation and Documentation

• Medication reconciliation should include vitamins, herbs, teas, and essential oils; probiotics have become common in hospital practice.
• Documentation should be clear and objective; record CAM use in clinical notes and forms.
• Drug interactions to be checked systematically:
  • St. John’s wort can reduce effectiveness of oral contraceptives and interact with other medications.
  • Garlic, ginseng, ginkgo, and other herbs may alter bleeding risk or interact with anticoagulants and cardiac meds.
  • Cross-check CAM therapies with current prescriptions to identify potential interactions.
• Informed patient-provider communication: emphasize informing the provider about CAM use; lack of disclosure can erode trust and complicate care, particularly in surgical or cancer treatment contexts.
• Evidence review and documentation of CAM effectiveness: clinicians should document patient-reported improvements (e.g., valerian for sleep) and monitor for adverse effects or lack of efficacy.

Pharmacology Concepts and Pharmacokinetics Foundations (as covered in lecture)

• Pharmacodynamics and pharmacokinetics basics are framed as essential to safe and effective nursing care:

  • Absorption: routes (oral, sublingual, IV, IM, subcutaneous) affect onset and bioavailability; first-pass metabolism can render some oral meds inactive.
  • Distribution: fat solubility and plasma protein binding (e.g., albumin) influence tissue distribution and central effects; lipophilic drugs cross the blood–brain barrier more readily.
  • Metabolism: liver is primary site; hepatic impairment or low albumin can increase free drug and risk toxicity; metabolism is affected by age and nutritional status (protein intake).
  • Excretion: primarily renal; assess kidney function (creatinine, GFR, urinary output) to gauge clearance and toxicity risk; some drugs also excreted via liver/bile, lungs, or breast milk.
  • First-pass effect: some oral meds may be inactivated by hepatic metabolism before reaching systemic circulation; non-oral routes may bypass this effect.
  • Pharmacokinetic concepts: onset, peak effect, duration, and half-life; therapeutic window and therapeutic index (TI) concepts.
  • Therapeutic index: high TI equals wide safety margin; low TI requires careful monitoring of drug levels and patient response.
  • Peak vs trough: peak is the highest plasma concentration; trough is the lowest; for narrow TI drugs, measure peak and trough to avoid toxicity.

• Practical clinical reasoning: use pharmacology categories to anticipate mechanisms, monitoring needs, and potential interactions without memorizing every drug by name.

• Therapeutic monitoring concepts:

  • Peak and trough for antibiotics with narrow TI (e.g., vancomycin, gentamicin) to prevent toxicity.
  • Plateaus and steady-state concepts: roughly 4–5 half-lives to reach steady-state dosing effectiveness; analogy used with morphine to illustrate peak, trough, and duration (see below).
  • Doling out medications to maintain continuous therapeutic effect without gaps; ensure coverage by dosing at appropriate times relative to the half-life.

• Drug safety and reversal concepts:

  • Reversal agents for emergencies (e.g., naloxone for opioid toxicity; reversal strategies depend on agent and route).
  • Safety-focused checks: pre-administration assessment, baseline vitals, allergies, organ function (liver and kidney), and potential drug–drug or drug–food interactions.
  • Dose safety and error handling: five-treatment checks (accuracy, allergies, response, document, reassess) and incident reporting if errors occur.

• Lab tests and monitoring for safety:

  • Coagulation monitoring: INR, PT, aPTT; monitoring PT/INR is crucial for patients on warfarin or other anticoagulants; assess for bleeding or bruising.
  • Liver function tests (LFTs) and CBC; kidney function (creatinine, GFR), BUN; liver enzymes reflect metabolism capacity and potential toxicity risks.
  • Electrolyte monitoring (e.g., potassium) in diuretic therapy to prevent dysrhythmias or digoxin toxicity.
  • Blood cultures and imaging considerations when interacting with contrast media and metformin as described.

• Onset, peak, and duration examples (from the lecture):

  • Warfarin: onset approximately $48 ext{–}72 ext{ hours}.$ Elimination may take weeks due to long half-life and cumulative effect.
  • Furosemide (IV): onset approximately $ext{onset} o 5 ext{ minutes}.$ Peak effect ≈ $1 ext{--}2 ext{ hours}.$ Duration ≈ $4 ext{--}6 ext{ hours}.$
  • Digoxin (cardiac glycoside): onset depends on route; oral onset generally slower; duration ≈ $3 ext{--}4 ext{ days}.$ Maintain potassium to reduce digoxin toxicity risk.
  • Carvedilol (beta-blocker): oral onset ≈ $1 ext{--}2 ext{ hours}.$ IV onset ≈ $5 ext{--}60 ext{ minutes}.$ Peak ≈ $2 ext{--}8 ext{ hours}.$ Duration ≈ $3 ext{--}4 ext{ days}$ (context-dependent).
  • Morphine (example for plateau concept): half-life ≈ $2 ext{--}3 ext{ hours}.$ Four to five half-lives to reach plateau; visualize as a “peak” and a “trough” to ensure continuous pain coverage.
  • Nitroglycerin/glyceryl nitrate exposure via patches: typically topical safety considerations (patch removal of old patches, rotation of sites, and monitoring for systemic effects).
  • Extended-release formulations: with multiple coating layers, first coat releases in GI tract to begin absorption; avoid crushing extended-release tablets.

• Units and dose formats commonly encountered:

  • Dose units in mg for many oral meds; diuretics and beta-blockers often dosed in mg; anticoagulants in units or mg; inhaled meds in mcg per inhalation; IV meds in mL/hr or mg/kg dosing depending on context.
  • Route-specific considerations (oral, IV, subcutaneous, inhaled, rectal/vaginal): check for swallowing ability, risk of aspiration, reservoir and delivery device, and patient education needs.

Specific Medications and Interactions Discussed (Illustrative Examples)

• Metformin and contrast media:
  • Metformin can be nephrotoxic in the setting of contrast exposure; assess kidney function and consider holding peri-imaging per institutional protocol to reduce risk of lactic acidosis and renal impairment.
  • When contrast is used, assess for potential interaction and renal clearance; monitor renal function and adjust peri-procedure plans.
• Warfarin (anticoagulant):
  • Onset: ≈ $48 ext{–}72 ext{ hours}$; clearance may take weeks.
  • Interactions: garlic (antiplatelet effects) and other herbs can increase bleeding risk; monitor PT/INR and signs of bleeding.
  • Perioperative planning: consider stopping certain herbs 1–2 weeks before surgery; verify bleeding risk with provider.
• Digoxin (cardiac glycoside):
  • Mechanism: increases cardiac contractility (calcium-mediated) and has cardiac conduction effects.
  • Monitoring: apical pulse for 1 minute before administration; monitor potassium (hypokalemia increases digoxin toxicity risk).
  • Interactions: diuretics (e.g., furosemide) can cause potassium shifts; maintain potassium balance.
  • Nutrition: maintain adequate potassium in diet to reduce risk of digoxin toxicity.
• Carvedilol (beta blocker):
  • Monitoring: assess BP and heart rate (apical pulse for 1 minute) before dosing.
  • Pharmacologic class effects: non-selective beta-blocker; monitor for hypotension and bradycardia.
• Furosemide (Lasix, loop diuretic):
  • Volume management: diuresis to reduce fluid overload; monitor kidney function and electrolytes (sodium, potassium).
  • Safety: IV administration details (rate) and monitoring for electrolyte disturbances.
• Nitroglycerin patches and topical agents:
  • Patch safety: rotate sites, remove old patches, wear on hairless intact skin, date and time every patch change; monitor for headaches and hypotension.
• Herbal and natural products discussed (interaction cautions):
  • Garlic: antiplatelet effects; avoid or monitor in patients on warfarin; check coagulation values.
  • Ginseng, Ginkgo, and Garlic: potential bleeding or cardiovascular interactions; review prior to procedures.
  • St. John’s wort: reduces oral contraceptive effectiveness; interacts with various meds.
  • Valerian: sleep aid; subjective improvement noted in some patients.
  • Licorice root: can cause hypertension and tachycardia; consider in patients with cardiac meds.
• Stimulants and other supplements: general need to assess safety and interactions; probiotics increasingly common in hospital settings.

Routes of Administration and Safety Protocols (Practical Nursing Skills)

• Oral medications:
  • Do not crush extended-release (ER) or intrinsic-release forms.
  • Sit the patient up at 90 degrees when taking pills; give with a full glass of water unless contraindicated.
  • Assess swallowing ability before giving medication orally.
• Sublingual and transdermal patches:
  • Monitor patch sites; rotate sites; remove old patches before applying new; date and time patches.
  • Be mindful of skin integrity and potential fentanyl or nitroglycerin patch safety concerns.
• Intravenous (IV) medications:
  • Check IV patency and monitor for infiltration and phlebitis; use infusion pump when possible to control rate.
  • Reversal strategies must be known and ready for emergencies; monitor patient closely after administration.
• Subcutaneous injections:
  • Common sites: deltoid, ventral gluteal; use Z-track technique for irritating medications to minimize leakage and discomfort.
• Inhaled medications:
  • Use spacer devices for children to ensure proper deposition in lungs; teach proper inhaler technique; hold breath for ~10 seconds after inhalation; wait ~1 minute between puffs; rinse mouth after use when applicable.
• Rectal and vaginal meds:
  • Left lateral Sims position for rectal meds; posterior wall insertion for vaginal meds; spacer devices recommended for children.
• Inhaler spacer technique and pediatric considerations:
  • Use spacer to maximize lung deposition and minimize oropharyngeal deposition.
• Safety and quality processes:
  • Five checks: accuracy, allergies, response, document, reassess.
  • Do not leave medications bedside; verify orders with pharmacy; use filter needles when drawing from ampoules.
  • Break the habit of hiding errors; report adverse events and injuries; ensure patient safety and learning from mistakes.
• Special cautions and practice points:
  • When giving diuretics, check kidney function and electrolytes; monitor BP, potassium, and sodium.
  • For anticoagulants, monitor INR and signs of bleeding; stop or modify herbs that affect bleeding risk during perioperative periods.
  • For opioids, monitor respiratory rate and use reversal agents if needed (e.g., naloxone) in emergencies.
  • Be mindful of the “therapeutic window” and adjust dosing to avoid toxicity, especially for narrow TI drugs (e.g., lithium, warfarin, digoxin).
• Practice-oriented tips and anecdotes:
  • The instructor emphasizes practical, scenario-based learning (e.g., choosing which drug to give first based on disease process and priorities).
  • Emphasis on using Lexicomp (or equivalent) for drug information; access in hospital systems is a practical skill for clinical documentation and patient safety.
  • The importance of questioning and applying pharmacology concepts to real patient scenarios (e.g., planning diuretic dosing in heart failure with fluid overload).

Pharmacology Practice Concepts: Examples Used in the Lecture

• Plateaus and steady-state concept illustrated with morphine and half-life:
  • Half-life of morphine: $t_{1/2} ext{(morphine)} \approx ext{2–3 hours}$.
  • To maintain continuous effect, dosing intervals should account for roughly 4–5 half-lives to achieve a plateau, ensuring consistent analgesia.
• Peak and trough monitoring for antibiotics with low TI (toxicity risk):
  • Peak and trough levels are used to avoid toxicity and ensure efficacy; drawing timing depends on route and drug.
• Lipid solubility and organ targeting:
  • Lipophilic (fat-soluble) drugs cross the blood–brain barrier more readily, influencing CNS effects and potential toxicity.
• First-pass metabolism:
  • Some oral medications may be significantly inactivated by hepatic metabolism; nonoral routes can bypass this to achieve effective bioavailability.
• Albumin binding and drug effect:
  • Low albumin increases the fraction of free drug, potentially increasing onset, intensity, and risk of toxicity.
• Renal and hepatic function gating:
  • Liver function and kidney function critically influence drug metabolism and excretion; organ dysfunction alters drug levels and safety.
• Therapeutic index and clinical decision-making:
  • High TI drugs have greater safety margins; low TI drugs require levels monitoring and more frequent assessment to prevent toxicity.

Ethical, Philosophical, and Practical Implications

• Respect for patient autonomy: honor beliefs about healing and CAM while guiding patients toward safe, evidence-based treatments.
• Safety and trust: the need for open dialogue about CAM use to reduce risk of adverse interactions and maintain trust in healthcare.
• Informed consent and shared decision-making: ensure patients understand risks/benefits of CAM vs conventional treatments, particularly in serious conditions like cancer.
• Education and competency: nurses should be trained to identify CAM use, understand potential interactions, and document CAM practices accurately for safe care.

Summary: Key Takeaways for Nursing Practice

• Integrate CAM thoughtfully with conventional care, assessing patient beliefs, readiness, and safety concerns.
• Always perform comprehensive medication reconciliation including CAM products; review potential interactions (e.g., garlic with warfarin; St. John’s wort with oral contraceptives).
• Use pharmacology knowledge (absorption, distribution, metabolism, excretion; therapeutic index; peak/trough monitoring) to anticipate effects and safety concerns.
• Monitor labs and vital signs to detect toxicity or adverse effects early; know when to use reversal agents and how to manage emergencies.
• Communicate clearly with patients and families; provide education at appropriate reading levels; use teach-back methods to ensure understanding.
• Document CAM use, patient preferences, and the effectiveness of CAM interventions to inform ongoing care plans.
• Be mindful of regional practice differences (e.g., hands-on therapeutic touch in some settings) while adhering to safety and infection control standards.
• Maintain professional skepticism and reliance on credible sources; recognize where evidence is lacking and avoid unsafe or unproven practices.
• Apply critical thinking and nursing judgment in prioritization, dosing, administration routes, and monitoring to deliver safe, effective care.